Fukushi Saori, Yoshino Hironori, Yoshizawa Atsushi, Kashiwakura Ikuo
Department of Frontier Materials Chemistry, Graduate School of Science and Technology, Hirosaki University, 3 Bunkyo-cho, Hirosaki, Aomori, 036-8561, Japan.
Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, 66-1 Hon-cho, Hirosaki, Aomori, 036-8564, Japan.
BMC Cancer. 2016 Jul 25;16:521. doi: 10.1186/s12885-016-2585-6.
We recently demonstrated the cytotoxicity of liquid crystal precursors (hereafter referred to as "mesogenic compounds") in the human non-small cell lung cancer (NSCLC) cell line A549 which carry wild-type p53. p53 mutations are observed in 50 % of NSCLC and contribute to their resistance to chemotherapy. To develop more effective and cancer-specific agents, in this study, we investigated the structure-activity relationships of mesogenic compounds with cytotoxic effects against multiple NSCLC cells.
The pharmacological effects of mesogenic compounds were examined in human NSCLC cells (A549, LU99, EBC-1, and H1299) and normal WI-38 human fibroblast. Analyses of the cell cycle, cell-death induction, and capsases expression were performed.
The 3-ring compounds possessing terminal alkyl and hydroxyl groups (compounds C1-C5) showed cytotoxicity in NSCLC cells regardless of the p53 status. The compounds C1 and C3, which possess a pyrimidine at the center of the core, induced G2/M arrest, while the compounds without a pyrimidine (C2, C4, and C5) caused G1 arrest; all compounds produced caspase-mediated cell death. These events occurred in a p53-independent manner. Furthermore, it was suggested that compounds induced cell death through p53-independent DNA damage-signaling pathway. Compounds C2, C4, and C5 did not show strong cytotoxicity in WI-38 cells, whereas C1 and C3 did. However, the cytotoxicity of compound C1 against WI-38 cells was improved by modulating the terminal alkyl chain lengths of the compound.
We showed the p53-indepdent structure-activity relationships of mesogenic compounds related to the cytotoxic effects. These structure-activity relationships will be helpful in the development of more effective and cancer-specific agents.
我们最近证明了液晶前体(以下简称“介晶化合物”)在携带野生型p53的人非小细胞肺癌(NSCLC)细胞系A549中的细胞毒性。在50%的NSCLC中观察到p53突变,这导致了它们对化疗的耐药性。为了开发更有效且针对癌症的药物,在本研究中,我们研究了介晶化合物对多种NSCLC细胞的细胞毒性作用的构效关系。
在人NSCLC细胞(A549、LU99、EBC-1和H1299)和正常WI-38人成纤维细胞中检测介晶化合物的药理作用。进行细胞周期、细胞死亡诱导和半胱天冬酶表达的分析。
具有末端烷基和羟基的三环化合物(化合物C1-C5)在NSCLC细胞中显示出细胞毒性,与p53状态无关。在核心中心具有嘧啶的化合物C1和C3诱导G2/M期阻滞,而没有嘧啶的化合物(C2、C4和C5)导致G1期阻滞;所有化合物均产生半胱天冬酶介导的细胞死亡。这些事件以p53非依赖的方式发生。此外,提示化合物通过p53非依赖的DNA损伤信号通路诱导细胞死亡。化合物C2、C4和C5在WI-38细胞中未显示出强细胞毒性,而C1和C3显示出强细胞毒性。然而,通过调节化合物的末端烷基链长度,提高了化合物C1对WI-38细胞的细胞毒性。
我们展示了与细胞毒性作用相关的介晶化合物的p53非依赖构效关系。这些构效关系将有助于开发更有效且针对癌症的药物。